
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Xcell Biosciences Expands AmplifyBio Partnership For Cell and Gene Therapies
Details : The collaboration aims to identify key elements for successful manufacture of TCR therapies. Experiments have progressed from in vitro to in vivo, to target human papillomavirus-positive tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
AmplifyBio And Xcell Partner To Manufacture TCR-T Cell Therapy
Details : The partnership aims to focus on TCR therapy and work through process development, preclinical analysis, and first-in-human trials using Xcellbio’s AVATAR Foundry platform for solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
